Last reviewed · How we verify
Non-alcoholic Fatty Liver Disease and Its Treatment
Dipeptidyl peptidase-4 inhibitors (DPP-4I), key regulators of the actions of incretin hormones, exert anti-hyperglycemic effects in type 2 diabetes mellitus (T2DM) patients. A major unanswered question concerns the potential ability of DPP-4I to improve intrahepatic lipid (IHL) content in nonalcoholic fatty liver disease (NAFLD) patients. The aim of this study was to evaluate the effects of sitagliptin on IHL in NAFLD patients.
Details
| Lead sponsor | Shanghai 10th People's Hospital |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 68 |
| Start date | Sun Jan 30 2011 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Dec 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- NAFLD
Interventions
- sitagliptin and metformin
- Sitagliptin
- Metformin